In vitro studies have shown that insulin-like growth factor (IGF) is a mitogen for breast cancer cells. However, the associations of plasma IGF-I with tumor histopathology in high-risk groups need further investigation. We hypothesize that plasma IGF-I and serum IGFBP3 concentrations in breast cancer patients may provide useful information on the progression of their disease, and determine the probability of recurrence and survival. We have carried out a retrospective study on 130 minority breast cancer patients. Plasma IGF-I and serum IGFBP3 were correlated with tumor histopathology, menopausal status, treatment modality, recurrence rates, and probability of survival. Plasma IGF-I and serum IGFBP3 were measured by radioimmunoassay. Our studies show that breast cancer patients have elevated plasma IGF-I and serum IGFBP3 levels. In addition we observed the following: IGF-I did not correlate with age and nodal stage. IGF-I and IGFBP3 increased with tumor size (T4). IGF-I did not correlate with estrogen receptor status, but did increase in progesterone-receptor-positive patients. IGF-I levels were higher in premenopausal patients and in women with cancer recurrence. Tamoxifen reduced IGF-I levels significantly and reduced the risk of recurrence. The survival probability was greater in patients with plasma IGF-I levels <120 ng/ml. In conclusion, lowering of plasma IGF-I may offer the following benefits: (a) reduce the risk of developing breast cancer in high-risk groups; (b) slow the progression of breast cancer in patients at early stages of cancer; (c) lower the risk of recurrence, and (d) increase the probability of survival.

Keywords:
Breast cancer, IGF-I, IGFBP3, Oncology, African-American women, Hispanic women
1.
Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 1989;10:68–91.
2.
Werner H, Adamo M, Roberts CT Jr, LeRoith D: Molecular and cellular aspects of insulin-like growth factor action. Vitam Horm 1994;48:1–58.
3.
Shimatsu A, Rotwein P: Mosaic evolution of the insulin-like growth factors. Organization, sequence and expression of the rat insulin-like growth factor I gene. J Biol Chem 1987;262:7894–7900.
4.
Clemmons D: IGF binding proteins: Regulation of cellular actions. Growth Regul 1992;2:80–87.
5.
Werner H, Woloschack M, Stannard B, Shen-Orr Z, Roberts CT Jr, LeRoith D: The insulin-like growth factor I receptor: Molecular biology, heterogeneity, and regulation; in LeRoith D (ed): Insulin-Like Growth Factors: Molecular and Cellular Aspects. Boca Raton, CRC Press, 1991, pp 17–47.
6.
Werner H, LeRoith D: The role of the insulin-like growth factor system in human cancer; in Vande Woude GF, Klein G (eds): Advances in Cancer Research. New York, Academic Press, 1996, vol 68, pp 184–223.
7.
Pratt SE, Pollack MN: Estrogen and antiestrogen modulation of human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 1993;53:5193–5198.
8.
Yee D, Jackson JG, Kozelsky TW, Figueroa JA: Insulin-like growth factor binding protein I expression inhibits insulin-like growth factor-I action in MCF-7 breast cancer cells. Cell Growth Differ 1994;5:73–77.
9.
Lee AV, Yee D: Insulin-like growth factors and breast cancer. Biomed Pharmacother 1995;49:415–421.
10.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ: Circulating concentrations of insulin-like growth factor-1 and risk of breast cancer. Lancet 1998;351:1393–1396.
11.
Chan JM, Stampfer MJ, Giovannucci E, et al: Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998;279:563–566.
12.
Barinaga M: Study suggests new way to gauge prostate cancer risk. Science 1998;279:475.
13.
Holly J: Insulin-like growth factor-1 and new opportunities for cancer prevention. Lancet 1998;351:1373–1374.
14.
Editorial: IGF binding protein-3 protease regulation: How sweet it is! J Clin Endocrinol Metab 1995;80:2279–2281.
15.
Jones JI, Clemmons DR: Insulin-like growth factors and their binding proteins: Biological actions. Endocr Rev 1995;16:3–16.
16.
Lahti EI, Knip M, Laatikainen TJ: Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 1994;74:618–624.
17.
Rocha RL, Hilsenbeck S, Jackson J, et al: Insulin-like growth factor binding protein-3 and insulin receptor substrate-1 in breast cancer: Correlation with clinical parameters and disease free survival. Clin Cancer Res 1997;3:103–109.
18.
Rocha RL, Hilsenbeck SG, Jackson JG, et al: Correlation of insulin-like growth factor-binding protein-3 messenger RNA with protein expression in primary breast cancer tissues: Detection of higher levels in tumors with poor prognostic features. J Natl Cancer Inst 1996;88:601–606.
19.
Pratt S, Pollak M: Insulin-like growth factor binding protein 3 (IGFBP3) inhibits estrogen-stimulated breast cancer cell proliferation. Biochem Biophys Res Commun 1994;198:292–297.
20.
Buckbinder L, Talbott R, Velasco-Miguel S, et al: Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 1995;377:646–649.
21.
Huynh H, Yang X, Pollak M: A role for insulin-like growth factor binding protein 5 in the antiproliferative action of the antiestrogen ICI 182780. Cell Growth Differ 1996;7:1501–1506.
22.
Gucev Z, Oh Y, Kelley K, et al: Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta 2-induced growth inhibition in human breast cancer cells. Cancer Res 1996;56:1545–1550.
23.
Underwood LE, Murphy MG: Radioimmunoassay of the somatomedins/insulin-like growth factors; in Patrano C, Peskar BA (eds): Radioimmunoassay in Basic and Clinical Pharmacology. Berlin, Springer, 1987, pp 561–574.
24.
Chatelain PG, Van Wyk JJ, Copeland CC, et al: Effects of in vitro action of serum proteases or exposure to acid on measurable immunoreactive somatomedin C in serum. J Clin Endocrinol Metab 1983;56:376–383.
25.
Clemmons DR, Underwood LE, Chatelain PG, et al: Liberation of immunoreactive somatomedin-C from its binding proteins by proteolytic enzymes and heparin. J Clin Endocrinol Metab 1983;56:384–389.
26.
Daughaday WH, Kapadia M, Moriz I: Serum somatomedin binding proteins: Physiologic significance and interference in radioligand assay. J Lab Clin Med 1987;109:355–363.
27.
Daughaday WH, Mariz IK, Blethen SL: Inhibition of access of basic somatomedin to membrane receptors and immunobinding sites. A comparison of radioreceptor and radioimmunological somatomedin in native and acid-ethanol extracted serum. J Clin Endocrinol Metab 1980;51:781–788.
28.
Baxter RC, Martin JL: Radioimmunoassay of growth factor hormone-dependent insulin-like growth factor binding protein in human plasma. J Clin Invest 1986;78:1504–1512.
29.
Yee D, Paik S, Lebovic GS, Marcus RR, Favoni RE, Cullen KJ, et al: Analysis of insulin-like growth factor I gene expression in malignancy: Evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989;3:509–517.
30.
Dickson RB, Lippman M: Growth factors in breast cancer. Endocr Rev 1995;16:559–589.
31.
Clemmons DR, Underwood LE: Clinical Review 59: Uses of human insulin-like growth factor-I in clinical conditions. J Clin Endocrinol Metab 1994;79:4–6.
32.
Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 1992;65:311–320.
33.
LeRoith D, Baserga R, Helman L, Roberts CT: Insulin-like growth factor and cancer. NIH Conference. Ann Intern Med 1995;22:54–59.
34.
Pollak MN: Endocrine effects of IGF-I on normal and transformed breast epithelial cells. Breast Cancer Res Treat 1998;47:209–217.
35.
Yee D: The insulin-like growth factors and breast cancer – revisited. Breast Cancer Res Treat 1998;47:197–199.
36.
Pollak M, Costantino J, Polychronakos C, et al: Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients. J Natl Cancer Inst 1990;82:1693–1697.
37.
Favoni RE, de Cupis A, Perrotta A, Sforzini S, Amoroso A, Pensa F, et al: Insulin-like growth factor-I (IGF-I) and IGF-binding proteins blood serum levels in women with early- and late-stage breast cancer: Mutual relationship and possible correlations with patients’ hormonal status. J Cancer Res Clin Oncol 1995;121:674–682.
38.
Peyrat JP, Bonneterre J, Hecquet B, Vennin P, Louchez MM, Fournier C, et al: Plasma insulin-like growth factor-I (IGF-I) concentrations in human breast cancer. Eur J Cancer 1993;29A:492–497.
39.
Friedl A, Jordan CV, Pollak M: Suppression of serum insulin-like growth factor I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993;29A:1368–1372.
40.
Yamamoto H, Sohmiya M, Oka N, Kato Y: Effect of aging and sex on plasma insulin-like growth factor I (IGF-I) levels in normal adults. Acta Endocrinol (Copenh) 1991;124:497–500.
41.
Pekonen F, Partanen S, Makinen T, et al: Receptors for epidermal growth factor and insulin-like growth factor I and their relation to steroid receptors in human breast cancer. Cancer Res 1988;48:1343–1347.
42.
Peyrat JP, Bonneterre J, Beuscart R, et al: Insulin-like growth factor I receptors in human breast cancer and their relation to estradiol and progesterone receptors. Cancer Res 1988;48:6429–6433.
43.
Lippman ME, Bolan G: Oestrogen-responsive human breast cancer in long-term tissue culture. Nature (Lond) 1975;256:592–593.
44.
Cole M, Jones CT, Todd IDH: A new antiestrogenic agent in late breast cancer: An early clinical appraisal of ICI 46,474. Br J Cancer 1971;25:270–275.
45.
Colletti RB, Roberts JD, DeVlin JT, Copeland KC: Effect of tamoxifen on plasma insulin-like growth factor I in patients with breast cancer. Cancer Res 1989;49:1882–1884.
46.
Helle SI, Holly JM, Tally M, et al: Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996;69:335–339.
47.
Helle SI, Anker GB, Tally M, et al: Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIE, insulin-like growth factor binding (IGFBP)-1 and IGFBP-3 in breast cancer patients. J Steroid Biochem Mol Biol 1996;57:167–171.
48.
Kawamura I, Lacey E, Mizota T, et al: The effect of droloxifene on the insulin-like growth factor-I-stimulated growth of breast cancer cells. Anticancer Res 1994;14:427–431.
49.
Bajetta E, Ferrai L, Celio L, et al: The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels. J Steroid Biochem Mol Biol 1997;63:261–267.
50.
Frost VJ, Helle SI, Lonning PE, et al: Effects of treatment with megestrol acetate, aminoglutethimide, or formestane on insulin-like growth factor (IGF) I and II, IGF-binding proteins (IGFBPs), and IGFBP-3 protease status in patients with advanced breast cancer. J Clin Endocrinol Metab 1996;81:2216–2221.
51.
Guvakova M, Surmacz E: Tamoxifen interferes with the insulin-like growth factor-I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997;57:2606–2610.
52.
Dunn SE, Hardman RA, Kari FW, Barrett JC: Insulin-like growth factor I (IGF-I) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced diverse anticancer drugs. Cancer Res 1997;57:2687–2693.
53.
Helle SI, Lonning PE: Insulin-like growth factors in breast cancer. Acta Oncol 1996;35(suppl 5):19–22.
© 1999 S. Karger AG, Basel
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.